false 0001680581 0001680581 2023-09-28 2023-09-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2023

FULCRUM THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38978   47-4839948
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

26 Landsdowne Street    
Cambridge, Massachusetts     02139
(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (617) 651-8851

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

  

Trading
Symbol(s)

  

Name of each exchange on which registered

 

Common stock, par value $0.001 per share   FULC   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum. Such amended and restated employment agreement, which has a 12-month term, did not modify Mr. Hayes’ current compensation or severance arrangements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      FULCRUM THERAPEUTICS, INC.
Date: October 2, 2023     By:  

/s/ Curtis Oltmans

      Name: Curtis Oltmans
      Title: Chief Legal Officer
v3.23.3
Document and Entity Information
Sep. 28, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001680581
Document Type 8-K
Document Period End Date Sep. 28, 2023
Entity Registrant Name FULCRUM THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38978
Entity Tax Identification Number 47-4839948
Entity Address, Address Line One 26 Landsdowne Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 651-8851
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol FULC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Fulcrum Therapeutics (NASDAQ:FULC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Fulcrum Therapeutics.
Fulcrum Therapeutics (NASDAQ:FULC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Fulcrum Therapeutics.